BACKGROUND: Antipsychotic treatment has been repeatedly found to be associated with an increased risk for venous thromboembolism in schizophrenia. The extent to which the propensity for venous thromboembolism is linked to antipsychotic medication alone or psychosis itself is unclear. The objective of this study was to determine whether markers of thrombogenesis are increased in psychotic patients who have not yet been treated with antipsychotic medication. METHODS: We investigated the plasma levels of markers indicating activation of coagulation (D-dimers and Factor VIII) and platelets (soluble P-selectin, sP-selectin) in an antipsychotic-naive group of fourteen men and eleven women with acute psychosis (age 29.1 ± 8.3 years, body mass index 23.6 ± 4.7), and twenty-five healthy volunteers were matched for age, gender and body mass index. RESULTS: D-dimers (median 0.38 versus 0.19 mg/l, mean 1.12 ± 2.38 versus 0.28 ± 0.3 mg/l; P = 0.003) and sP-selectin (median 204.1 versus 112.4 ng/ml, mean 209.9 ± 124 versus 124.1 ± 32; P = 0.0005) plasma levels were significantly increased in the group of patients with acute psychosis as compared with healthy volunteers. We found a trend (median 148% versus 110%, mean 160 ± 72.5 versus 123 ± 62.5; P = 0.062) of increased plasma levels of factor VIII in psychotic patients as compared with healthy volunteers. CONCLUSIONS: The results suggest that at least a part of venous thromboembolic events in patients with acute psychosis may be induced by pathogenic mechanisms related to psychosis rather than by antipsychotic treatment. Finding an exact cause for venous thromboembolism in psychotic patients is necessary for its effective treatment and prevention.

Dept of Psychiatry Charles University Prague Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové Czech Republic

See more in PubMed

Brown S. Excess mortality of schizophrenia. A metanalysis. Br J Psychiatry. 1997;171:502–508. doi: 10.1192/bjp.171.6.502. PubMed DOI

Leucht S, Burkard T, Henderson J, Maj M, Sartorius M. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116:317–333. doi: 10.1111/j.1600-0447.2007.01095.x. PubMed DOI

Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic mediaction and mortality. Br J Psychiatry. 2006;188:122–127. doi: 10.1192/bjp.188.2.122. PubMed DOI

Osborn DP, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. BMC Psychiatry. 2008;8:84. doi: 10.1186/1471-244X-8-84. PubMed DOI PMC

Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123–1131. doi: 10.1001/archpsyc.64.10.1123. PubMed DOI

Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 2009;113:1–11. doi: 10.1016/j.schres.2009.05.018. PubMed DOI

Osinbowale O, Ali L, Chi YW. Venous thromboembolism: a clinical review. Postgrad Med. 2010;122:54–65. doi: 10.3810/pgm.2010.03.2122. PubMed DOI

Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost. 1997;78:1–6. PubMed

Virchow R. Collected Works on Scientific Medicine. Frankfurt: Staatsdruckerei; 1856. Phlebitis and thrombosis in the vascular system.

Malý R, Masopust J, Hosák L, Konupčíková K. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci. 2008;62:3–8. PubMed

DeHert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) Eur Psychiatry. 2009;24:412–424. doi: 10.1016/j.eurpsy.2009.01.005. PubMed DOI

Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, Fonseca V, Winstead D. Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veteran Health Administration. BMC Psychiatry. 2009;9:80. doi: 10.1186/1471-244X-9-80. PubMed DOI PMC

Hägg S, Spigset O. Antipsychotic-induced venous tromboembolism: a review of the evidence. CNS Drugs. 2002;16:765–776. PubMed

Zornberg GI, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case control study. Lancet. 2000;356:1219–1223. doi: 10.1016/S0140-6736(00)02784-7. PubMed DOI

Liperoti R, Pedone C, Lapane KL. et al.Venous thromboembolism among eldery patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165:2677–2682. doi: 10.1001/archinte.165.22.2677. PubMed DOI

Lacut K, Le Gal G, Couturaud F, Cornily G, Leroyer C, Mottier D, Oger E. Association between antipsychotic drugs, antidepressant drugs and venous thrmoboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol. 2007;21:643–650. doi: 10.1111/j.1472-8206.2007.00515.x. PubMed DOI

Jönsson AK, Brudin L, Ahlner J, Hedenmalm K, Ericsson A, Hägg S. Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series. Int Clin Psychopharmacol. 2008;23:263–268. PubMed

Jönsson AK, Horváth-Puhó E, Hägg S, Pedersen L, Sorensen HT. Antipsychotics and risk of venous thromboembolism: A population-based case-control study. Clin Epidemiol. 2009;1:19–26. PubMed PMC

Kamijo Y, Soma K, Nagai T, Kurihara K, Ohwada T. Acute massive pulmonary thromboembolism associated with risperidone and convetional phenothiazines. Circ J. 2003;67:46–48. doi: 10.1253/circj.67.46. PubMed DOI

Waage IM, Gedde-Dahl A. Pulmonary embolism possibly associated with olanzapine treatment. BMJ. 2003;327:384. doi: 10.1136/bmj.327.7428.1384. PubMed DOI PMC

Hägg S, Tatting P, Spigset O. Olanzapine and venous thromboembolism. Int Clin Psychopharmacol. 2003;18:299–300. PubMed

Borras L, Eytan A, de Timary P, Constant EL, Huguelet P, Hermans C. Pulmonary thromboembolism associated with olanzapine and risperidone. J Emerg Med. 2007;35:159–161. doi: 10.1016/j.jemermed.2007.07.074. PubMed DOI

Malý R, Masopust J, Hosák L, Urban A. Four cases of venous thromboembolism associated with olanzapine. Psychiatry Clin Neurosci. 2009;63:116–118. PubMed

Hägg S, Bate A, Stahl M, Spigset O. Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf. 2008;31:685–694. PubMed

Lazarus A. Physical restraints, thromboembolism, and death in 2 patients. J Clin Psychiatry. 2001;63:207–208. doi: 10.4088/JCP.v62n0312d. PubMed DOI

Hägg S, Jönsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf. 2009;8:537–547. PubMed

World Health Organisation. International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Version for 2007. Geneva. 2006.

Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999;82:610–619. PubMed

Iwata Y, Suzuki K, Nakamura K, Matsuzaki H, Sekine Y, Tsuchiya KJ, Sugihara G, Kawai M, Minabe Y, Takei N, Mori N. Increased levels of serum soluble L-selectin in unmedicated patiens with schizophrenia. Schizophr Res. 2007;89:154–160. doi: 10.1016/j.schres.2006.08.026. PubMed DOI

Walsh MT, Ryan M, Hillmann A, Condren R, Kenny D, Dinan T, Thakore JH. Elevated expression of integrin alpha(IIb) beta(IIIa) in drug-naïve, first-episode schizophrenic patients. Biol Psychiatry. 2002;52:874–879. doi: 10.1016/S0006-3223(02)01400-2. PubMed DOI

Morioka H, Nagatomo I, Yamada K, Horikiri Y, Okamura H, Takigawa M. Deep venous thrombosis of the leg due to psychiatric stupor. Psychiatry Clin Neurosci. 1997;51:323–326. doi: 10.1111/j.1440-1819.1997.tb03206.x. PubMed DOI

Ginsberg JS, Wells PS, Kearon C, Anderson D, Crowther M, Weitz JI, Bormanis J, Brill-Edwards P, Turpie AG, MacKinnon B, Gent M, Hirsh J. Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. Ann Intern Med. 1998;129:1006–1011. PubMed

Hindersin P, Siegmund R, Körting HJ. Thrombophiliac diatheses as disorders of haemostasis in acute psychosis. Psych Neurol Med Psychol. 1984;36:702–709. PubMed

Andreescu ACM, Cushman M, Rosendaal FR. D-Dimer as a risk factor for deep vein thrombosis: The Leiden thrombophilia study. Thromb Haemost. 2002;87:47–51. PubMed

Mathur A, Robinson MS, Cotton J, Martin JF, Erusalimsky JD. Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost. 2001;85:989–994. PubMed

Ay C, Jungbauer LV, Sailer T, Tengler T, Koder S, Kaider A, Panzer S, Quehenberger P, Pabinger I, Mannhalter C. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem. 2007;53:1235–1243. doi: 10.1373/clinchem.2006.085068. PubMed DOI

Smith A, Quarmby JW, Collins M, Lockhart SM, Burnand KG. Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis. Thromb Haemost. 1999;82:1593–1599. PubMed

Rectenwald JE, Myers DD Jr, Hawley AE, Longo C, Henke PK, Guire KE, Schmaier AH, Wakefield TW. D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost. 2005;94:1312–1317. PubMed

Blann AD, Noteboom WM, Rosendaal FR. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect? Br J Haematol. 2000;108:191–193. doi: 10.1046/j.1365-2141.2000.01813.x. PubMed DOI

Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematom. 2007;44:62–69. doi: 10.1053/j.seminhematol.2007.02.004. PubMed DOI PMC

Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Wilebrand factor on recurrence of deep-vein thrombosis. Lancet. 1995;345:152–155. doi: 10.1016/S0140-6736(95)90166-3. PubMed DOI

Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets

Venous Thromboembolism as an Adverse Effect During Treatment With Olanzapine: A Case Series